



Company Contact:
Richard Gabriel
CEO and President
941 366-3400

-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848

FOR IMMEDIATE RELEASE:

**DNAPRINT GENOMICS' ANCESTRY E-SYMPOSIUM NOW AVAILABLE
FOR STREAMING OR DOWNLOAD**

Live Webcast Draws More Than 800 Participants

SARASOTA, Fla., July 24, 2006 – DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that its Ancestry e-Symposium, which drew more than 800 participants, including genealogy professionals, members of the public and other interested parties, is now available for streaming or download from an archived Webcast.

“We were extremely pleased with the results of the first global e-Symposium on Ancestry, which attracted so many participants from so many places,” stated DNAPrint President and Chief Executive Officer Richard Gabriel. “Clearly, there is worldwide interest in exploring the scientific underpinnings of DNA research. We believe people are especially interested in DNA research to trace ancestry and identify individual characteristics that not only define personal identity but can also aid in the diagnosis and treatment of certain diseases. We hope that this is the first of many public forums into the mysteries and science of DNA sponsored by our Company.”

The Ancestry e-Symposium featured lectures and slide presentations by seven presenters, who answered questions from many of the participants who logged on to the live Webcast. The live Webcast took place on Wednesday, July 19 and a complete archived version can be accessed free of charge at www.ancestry.e-symposium.com or on the Company’s Website at www.dnprint.com

Highlights of e-Symposium presentations:

- ❑ Gavin Menzies, author, *1421- The Year China Discovered the World*. Descendants of Chinese crewmen who survived shipwrecks off the North Carolina and Virginia coast now are living in the Appalachian mountain area of the U.S. The first Europeans who came to North Carolina found Chinese artifacts.
- ❑ Jason Eshelman, Senior Research Director, Trace Genetics, Inc, a DNAPrint subsidiary. Ancient DNA finds should be treated with skepticism. A report about dinosaur DNA being recovered turned out to be human DNA. The sample was contaminated by those handling it. Always make certain that Ancient DNA analysis is done utilizing the proper protocols.
- ❑ Edward Ball, author, *Genealogy & DNA Technology*. An antique desk containing packets of hair locks, some 175 years old, initiated a quest to learn about Mr. Ball’s family heritage, revealing family ties to Europe and the African country of Senegal.

(MORE)

- ❑ Brian M. Kemp, Ph.D. candidate, Department of Anthropology, University of California, Davis. Evidence shows that the first humans entered the Americas approximately 15,000 years ago during a glacial period.
- ❑ Jeff Long, Professor of Human Genetics and Adjunct Professor of Biostatistics, University of Michigan. A primer on the genetic structure of populations and the difficulties inherent in distinguishing between and among races of humans.
- ❑ Toomas Kivisild, Senior Scientist, Estonian Biocentre. Genetic variations in Asian and sub-Asian populations.
- ❑ Tony N. Frudakis, Ph. D., Chief Scientific Officer, DNAPrint Genomics, Inc., a DNAPrint subsidiary. A discussion of the rich nature of DNA around the world and how Ancestry Information Markers (AIM) are playing a key role in the development of pharmaceuticals and forensic technologies.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

##